Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Always Active
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.

Activity Report 2018

Download in: Deutsch | 日本語

The Global Antibiotic Research and Development Partnership have built on last year’s successes and made significant progress in addressing Gram-negative drug-resistant infections in children, newborns with sepsis, and sexually-transmitted infections. The work we have done this year includes conducting three clinical trials and preparing to launch our first phase III clinical trial for a potential new treatment for gonorrhoea. Our discovery and exploratory research, and memory recovery and asset evaluation programme, which has evaluated over 80 assets, gives us the flexibility to expand our current portfolio.

Looking forward to 2019, we are developing a new and ambitious business plan. With an established track record, we are a trusted partner bringing together the public and private sector to drive innovation and access to address public health priorities. As we continue to make good progress, we thank all of you who made it happen – our donors, our partners, and, of course, our team. We are delighted that all the commitments made at GARDP’s first pledging event have been realized. For this we are grateful and look forward to growing our collaboration and engagement in the years to come.